Science

Sustainable Pipeline of Innovative Immunotherapies

The success of first-generation immunotherapies has highlighted both the promise of modulating the immune system for therapeutic purposes and the need for a deeper understanding of the immune ecosystem on a personalized level. We are building a diversified and sustainable pipeline of immunomodulatory therapeutic antibodies targeting multiple cell types for the treatment of cancer and autoimmune disease.

Highlights

Multi-faceted approach for targeting key immunomodulatory cell types and pathways, with programs ranging from early discovery to CMC stages

Ultra-high throughput single-cell proprietary approaches for antibody and predictive biomarker discovery to accelerate clinical development

Fast-paced antibody engineering guided by machine learning technology results in activity-optimized drug designs

Pipeline programs are supported by novel biological insights from world-class collaborators in Immunology and Oncology

Pipeline

Target Discovery of Molecules Leading to New Generation of Precision Immunotherapies

We take a multi-faceted approach to target the immune system, including depletion of key immunosuppressive cell types to enhance anti-tumor immunity, blocking of pleiotropic immune modulators governing multiple pathways to shift the balance of immune system activity, and activation of signaling pathways to expand immune cell subsets.

Our therapeutic targets come from a variety of sources, including:

  • Novel and complex targets from scientific publications where our CelliGOTM technology offers the potential to identify differentiated antibodies
  • Collaborations with leading immunologists and oncologists around the world to validate potential proprietary novel targets and develop therapeutic antibodies against them
  • Data mining from patient samples to identify immunosuppressive cell types and mechanisms driving resistance to current immunotherapies
  • Profiling of patient immune repertoires to identify antibodies being produced against novel targets
  • State-of-the-art antibody engineering capabilities, including a proprietary panel of Fc variants with enhanced effector functions

Global Translational Clinical Network Enabling a Deeper Understanding of Disease Biology

We apply our unique worldwide translational capabilities to support our internal pipeline from early target identification to the clinic, resulting in better treatment outcomes.

  • Synergistic collaborations with top academic institutions and world-class clinicians
  • Deep understanding of disease biology and unique single-cell profiling technologies to advance drug discovery and development efforts
  • Innovative interface combining biological/clinical science and single-cell technologies
  • Ability to dissect disease heterogeneity through single-cell profiling
  • Broad access to patient samples worldwide with a variety of indications

Data Intelligence Matching Therapies to Patients

Fueled by data from our single-cell technology, we unleash the power of artificial intelligence and machine learning for better target and biomarker discovery.

  • Resolve complex biology by deep phenotypic characterization of different immune cell types paired with functional readouts
  • Sophisticated algorithms exploit the rich data structure of single-cell data
  • In silico analytical capabilities facilitated by our AbSolution™ software guide fast-paced engineering and results in activity optimized drug designs
  • Results in therapeutics that are precisely tailored to benefit patients

Versatile Single-Cell Platform to Transform Drug Discovery and Development

We apply our proprietary single-cell functional antibody screening CelliGO platform and unique immune profiling Drug Intelligent Science (DISTM) capabilities to enable rapid identification of differentiated therapeutic molecules and significantly enhance clinical probability of success

Key advantages of CelliGO

  • Ultra-high-throughput antibody selection with millions of B-cells analyzed per campaign
  • Deep mining ability of the immune repertoire in a species agonistic manner
  • Enable to explore challenging targets such as multi-transmembrane proteins
  • Rapid turn-around time from screening to sequences
  • Antibody sequencing analysis and selection guided by our integrated bioinformatics platform AbSolution

Drug Intelligent Science: Pioneering novel biomarker development increases probability of success in Phase I/II clinical trials

  • Ability to examine the disease biology by combining single cell phenotype, functionality and genotype
  • Artificial intelligence and machine learning are leveraged for better drug design and patient selection using single-cell data
  • Unprecedented high-throughput analysis enables deep profiling of rare cell populations
  • Ability to provide unique insight for patient stratification and identification of predictive biomarkers, leading to clinical trials with enhanced probability of success

Peer-Reviewed
Scientific Publications and Posters

We continue to validate, strengthen and leverage our single-cell platform with world leaders and pioneers in immunology and cancer research. Our high scientific standards have been validated in numerous peer-reviewed publications and conference presentations.

Publications
HiFiBiO Therapeutics and Leading Academic Institutions Demonstrate Breakthrough Single-Cell Approach for Novel Biomarker Discovery to Combat Cancer

The Nature Genetics publication describes a novel high-throughput single-cell ChIP-seq approach to studying heterogeneity of chromatin states within complex biological systems. Our proprietary single-cell CelliGO platform and unique DIS capabilities were used to probe why certain disease cells are resistant to available therapeutics.

Publications
Shared Insights About Guiding Principles of Open Collaboration in Drug Discovery Today From HiFiBiO CEO Liang Schweizer and COO Jeff He

Guiding principles of value creation through collaborative innovation in pharmaceutical research HiFiBiO CEO Liang Schweizer and COO Jeff He outline the importance of breaking down common barriers in collaborations, propose four guiding principles for such co-operation and offer a framework to reach value inflection points quicker.

Publications
Single-Cell Deep Phenotyping of lgG-Secreting Cells for High-Resolution Immune Monitoring

The Nature Biotechnology manuscript details DropMap, “a powerful and elegant technology for the phenotypic analysis of antibody-secreting cells (ASCs) at the single-cell level with unprecedented throughput and resolution.” This droplet microfluidics approach was developed with collaborators from ESPCI and Institut Pasteur.

Posters
Antibody Discovery by Deep Mining of Immune Repertoires

Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study